Efficacy of infliximab in extrapulmonary sarcoidosis

Results from a randomised trial

M. A. Judson, R. P. Baughman, U. Costabel, S. Flavin, K. H. Lo, M. S. Kavuru, M. Drent, D. A. Culver, G. S. Davis, C. M. Fogarty, G. W. Hunninghake, A. S. Teirstein, M. Mandel, D. McNally, L. Tanoue, L. Newman, Y. Wasfi, H. Patrick, M. D. Rossman, G. Raghu & 18 others O. Sharma, D. Wilkes, H. Yeager, J. F. Donahue, M. Kaye, N. Sweiss, N. Vetter, M. Thomeer, M. Brutsche, L. Nicod, D. Valeyre, P. Chanez, C. Albera, J. Grutters, H. Hoogsteden, J. Muller-Quernheim, R. Bonnet, F. Kanniess

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

The aim of the present study was to investigate the efficacy of infliximab for the treatment of extrapulmonary sarcoidosis. A prospective, randomised, double-blind, placebo-controlled trial was conducted, with infliximab at 3 and 5 mg·kg-1 body weight administered over 24 weeks. Extrapulmonary organ severity was determined by a novel severity tool (extrapulmonary physician organ severity tool; ePOST) with an adjustment for the number of organs involved (ePOSTadj). In total, 138 patients enrolled in the trial of infliximab versus placebo for the treatment of chronic corticosteroid-dependent pulmonary sarcoidosis. The baseline severity of extrapulmonary organ involvement, as measured by ePOST, was similar across treatment groups. After 24 weeks of drug-therapy study, the change from baseline to week 24 in ePOST was greater for the combined infliximab group compared with the placebo group. After adjustment for the number of extrapulmonary organs involved, the improvement in ePOSTadj observed in the combined infliximab group was also greater than that observed in placebo-treated patients, after 24 weeks of therapy. The improvements in ePOST and ePOSTadj were not maintained during a subsequent 24-week washout period. Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study. Copyright

Original languageEnglish
Pages (from-to)1189-1196
Number of pages8
JournalEuropean Respiratory Journal
Volume31
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Sarcoidosis
Placebos
Adrenal Cortex Hormones
Pulmonary Sarcoidosis
Therapeutics
Infliximab
Body Weight
Physicians
Drug Therapy

Keywords

  • Extrathoracic
  • Infliximab
  • Sarcoidosis
  • Severity
  • Therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Judson, M. A., Baughman, R. P., Costabel, U., Flavin, S., Lo, K. H., Kavuru, M. S., ... Kanniess, F. (2008). Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial. European Respiratory Journal, 31(6), 1189-1196. https://doi.org/10.1183/09031936.00051907

Efficacy of infliximab in extrapulmonary sarcoidosis : Results from a randomised trial. / Judson, M. A.; Baughman, R. P.; Costabel, U.; Flavin, S.; Lo, K. H.; Kavuru, M. S.; Drent, M.; Culver, D. A.; Davis, G. S.; Fogarty, C. M.; Hunninghake, G. W.; Teirstein, A. S.; Mandel, M.; McNally, D.; Tanoue, L.; Newman, L.; Wasfi, Y.; Patrick, H.; Rossman, M. D.; Raghu, G.; Sharma, O.; Wilkes, D.; Yeager, H.; Donahue, J. F.; Kaye, M.; Sweiss, N.; Vetter, N.; Thomeer, M.; Brutsche, M.; Nicod, L.; Valeyre, D.; Chanez, P.; Albera, C.; Grutters, J.; Hoogsteden, H.; Muller-Quernheim, J.; Bonnet, R.; Kanniess, F.

In: European Respiratory Journal, Vol. 31, No. 6, 06.2008, p. 1189-1196.

Research output: Contribution to journalArticle

Judson, MA, Baughman, RP, Costabel, U, Flavin, S, Lo, KH, Kavuru, MS, Drent, M, Culver, DA, Davis, GS, Fogarty, CM, Hunninghake, GW, Teirstein, AS, Mandel, M, McNally, D, Tanoue, L, Newman, L, Wasfi, Y, Patrick, H, Rossman, MD, Raghu, G, Sharma, O, Wilkes, D, Yeager, H, Donahue, JF, Kaye, M, Sweiss, N, Vetter, N, Thomeer, M, Brutsche, M, Nicod, L, Valeyre, D, Chanez, P, Albera, C, Grutters, J, Hoogsteden, H, Muller-Quernheim, J, Bonnet, R & Kanniess, F 2008, 'Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial', European Respiratory Journal, vol. 31, no. 6, pp. 1189-1196. https://doi.org/10.1183/09031936.00051907
Judson, M. A. ; Baughman, R. P. ; Costabel, U. ; Flavin, S. ; Lo, K. H. ; Kavuru, M. S. ; Drent, M. ; Culver, D. A. ; Davis, G. S. ; Fogarty, C. M. ; Hunninghake, G. W. ; Teirstein, A. S. ; Mandel, M. ; McNally, D. ; Tanoue, L. ; Newman, L. ; Wasfi, Y. ; Patrick, H. ; Rossman, M. D. ; Raghu, G. ; Sharma, O. ; Wilkes, D. ; Yeager, H. ; Donahue, J. F. ; Kaye, M. ; Sweiss, N. ; Vetter, N. ; Thomeer, M. ; Brutsche, M. ; Nicod, L. ; Valeyre, D. ; Chanez, P. ; Albera, C. ; Grutters, J. ; Hoogsteden, H. ; Muller-Quernheim, J. ; Bonnet, R. ; Kanniess, F. / Efficacy of infliximab in extrapulmonary sarcoidosis : Results from a randomised trial. In: European Respiratory Journal. 2008 ; Vol. 31, No. 6. pp. 1189-1196.
@article{872fa8a17e1040f3a1194af1d0e50286,
title = "Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial",
abstract = "The aim of the present study was to investigate the efficacy of infliximab for the treatment of extrapulmonary sarcoidosis. A prospective, randomised, double-blind, placebo-controlled trial was conducted, with infliximab at 3 and 5 mg·kg-1 body weight administered over 24 weeks. Extrapulmonary organ severity was determined by a novel severity tool (extrapulmonary physician organ severity tool; ePOST) with an adjustment for the number of organs involved (ePOSTadj). In total, 138 patients enrolled in the trial of infliximab versus placebo for the treatment of chronic corticosteroid-dependent pulmonary sarcoidosis. The baseline severity of extrapulmonary organ involvement, as measured by ePOST, was similar across treatment groups. After 24 weeks of drug-therapy study, the change from baseline to week 24 in ePOST was greater for the combined infliximab group compared with the placebo group. After adjustment for the number of extrapulmonary organs involved, the improvement in ePOSTadj observed in the combined infliximab group was also greater than that observed in placebo-treated patients, after 24 weeks of therapy. The improvements in ePOST and ePOSTadj were not maintained during a subsequent 24-week washout period. Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study. Copyright",
keywords = "Extrathoracic, Infliximab, Sarcoidosis, Severity, Therapy",
author = "Judson, {M. A.} and Baughman, {R. P.} and U. Costabel and S. Flavin and Lo, {K. H.} and Kavuru, {M. S.} and M. Drent and Culver, {D. A.} and Davis, {G. S.} and Fogarty, {C. M.} and Hunninghake, {G. W.} and Teirstein, {A. S.} and M. Mandel and D. McNally and L. Tanoue and L. Newman and Y. Wasfi and H. Patrick and Rossman, {M. D.} and G. Raghu and O. Sharma and D. Wilkes and H. Yeager and Donahue, {J. F.} and M. Kaye and N. Sweiss and N. Vetter and M. Thomeer and M. Brutsche and L. Nicod and D. Valeyre and P. Chanez and C. Albera and J. Grutters and H. Hoogsteden and J. Muller-Quernheim and R. Bonnet and F. Kanniess",
year = "2008",
month = "6",
doi = "10.1183/09031936.00051907",
language = "English",
volume = "31",
pages = "1189--1196",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - Efficacy of infliximab in extrapulmonary sarcoidosis

T2 - Results from a randomised trial

AU - Judson, M. A.

AU - Baughman, R. P.

AU - Costabel, U.

AU - Flavin, S.

AU - Lo, K. H.

AU - Kavuru, M. S.

AU - Drent, M.

AU - Culver, D. A.

AU - Davis, G. S.

AU - Fogarty, C. M.

AU - Hunninghake, G. W.

AU - Teirstein, A. S.

AU - Mandel, M.

AU - McNally, D.

AU - Tanoue, L.

AU - Newman, L.

AU - Wasfi, Y.

AU - Patrick, H.

AU - Rossman, M. D.

AU - Raghu, G.

AU - Sharma, O.

AU - Wilkes, D.

AU - Yeager, H.

AU - Donahue, J. F.

AU - Kaye, M.

AU - Sweiss, N.

AU - Vetter, N.

AU - Thomeer, M.

AU - Brutsche, M.

AU - Nicod, L.

AU - Valeyre, D.

AU - Chanez, P.

AU - Albera, C.

AU - Grutters, J.

AU - Hoogsteden, H.

AU - Muller-Quernheim, J.

AU - Bonnet, R.

AU - Kanniess, F.

PY - 2008/6

Y1 - 2008/6

N2 - The aim of the present study was to investigate the efficacy of infliximab for the treatment of extrapulmonary sarcoidosis. A prospective, randomised, double-blind, placebo-controlled trial was conducted, with infliximab at 3 and 5 mg·kg-1 body weight administered over 24 weeks. Extrapulmonary organ severity was determined by a novel severity tool (extrapulmonary physician organ severity tool; ePOST) with an adjustment for the number of organs involved (ePOSTadj). In total, 138 patients enrolled in the trial of infliximab versus placebo for the treatment of chronic corticosteroid-dependent pulmonary sarcoidosis. The baseline severity of extrapulmonary organ involvement, as measured by ePOST, was similar across treatment groups. After 24 weeks of drug-therapy study, the change from baseline to week 24 in ePOST was greater for the combined infliximab group compared with the placebo group. After adjustment for the number of extrapulmonary organs involved, the improvement in ePOSTadj observed in the combined infliximab group was also greater than that observed in placebo-treated patients, after 24 weeks of therapy. The improvements in ePOST and ePOSTadj were not maintained during a subsequent 24-week washout period. Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study. Copyright

AB - The aim of the present study was to investigate the efficacy of infliximab for the treatment of extrapulmonary sarcoidosis. A prospective, randomised, double-blind, placebo-controlled trial was conducted, with infliximab at 3 and 5 mg·kg-1 body weight administered over 24 weeks. Extrapulmonary organ severity was determined by a novel severity tool (extrapulmonary physician organ severity tool; ePOST) with an adjustment for the number of organs involved (ePOSTadj). In total, 138 patients enrolled in the trial of infliximab versus placebo for the treatment of chronic corticosteroid-dependent pulmonary sarcoidosis. The baseline severity of extrapulmonary organ involvement, as measured by ePOST, was similar across treatment groups. After 24 weeks of drug-therapy study, the change from baseline to week 24 in ePOST was greater for the combined infliximab group compared with the placebo group. After adjustment for the number of extrapulmonary organs involved, the improvement in ePOSTadj observed in the combined infliximab group was also greater than that observed in placebo-treated patients, after 24 weeks of therapy. The improvements in ePOST and ePOSTadj were not maintained during a subsequent 24-week washout period. Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study. Copyright

KW - Extrathoracic

KW - Infliximab

KW - Sarcoidosis

KW - Severity

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=49649098822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649098822&partnerID=8YFLogxK

U2 - 10.1183/09031936.00051907

DO - 10.1183/09031936.00051907

M3 - Article

VL - 31

SP - 1189

EP - 1196

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 6

ER -